1 citations
,
March 2025 in “Skin Appendage Disorders” Baricitinib for alopecia areata may rarely cause eye issues like keratitis.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
1 citations
,
June 2023 in “American Journal of Clinical Dermatology” Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.